|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/11/22 Accolade, Inc. 10-Q 11/30/21 68:9.1M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.52M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
10: R1 Document and Entity Information HTML 77K
11: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 110K
12: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 29K
(Parenthetical)
13: R4 Condensed Consolidated Statements of Operations HTML 85K
(Unaudited)
14: R5 Condensed Consolidated Statements of Convertible HTML 134K
Preferred Stock and Stockholders' Equity (Deficit)
(Unaudited)
15: R6 Condensed Consolidated Statements of Convertible HTML 22K
Preferred Stock and Stockholders' Deficit
(Unaudited) (Parenthetical)
16: R7 Condensed Consolidated Statements of Cash Flows HTML 127K
(Unaudited)
17: R8 Background HTML 23K
18: R9 Basis of Presentation and Summary of Significant HTML 67K
Accounting Policies
19: R10 Revenue HTML 44K
20: R11 Acquisitions HTML 130K
21: R12 Goodwill and Intangible Assets HTML 57K
22: R13 Fair Value Measurements HTML 74K
23: R14 Debt HTML 45K
24: R15 Equity-based Compensation HTML 122K
25: R16 Income Taxes HTML 27K
26: R17 Net Loss Per Share Attributable to Common HTML 100K
Stockholders
27: R18 Commitments and Contingencies HTML 26K
28: R19 Change Healthcare Joint Development Agreement HTML 34K
29: R20 Basis of Presentation and Summary of Significant HTML 83K
Accounting Policies (Policies)
30: R21 Basis of Presentation and Summary of Significant HTML 55K
Accounting Policies (Tables)
31: R22 Revenue (Tables) HTML 29K
32: R23 Acquisitions (Tables) HTML 109K
33: R24 Goodwill and Intangible Assets (Tables) HTML 58K
34: R25 Fair Value Measurements (Tables) HTML 74K
35: R26 Debt (Tables) HTML 26K
36: R27 Equity-based Compensation (Tables) HTML 116K
37: R28 Net Loss Per Share Attributable to Common HTML 101K
Stockholders (Tables)
38: R29 Change Healthcare Joint Development Agreement HTML 29K
(Tables)
39: R30 Basis of Presentation and Summary of Significant HTML 39K
Accounting Policies - Basis of Presentation and
Principles of Consolidation (Details)
40: R31 Basis of Presentation and Summary of Significant HTML 30K
Accounting Policies - Capitalized Internal-Use
Software Costs (Details)
41: R32 Basis of Presentation and Summary of Significant HTML 39K
Accounting Policies - Concentration of Credit Risk
(Details)
42: R33 Revenue - Revenue and Deferred Revenue (Details) HTML 38K
43: R34 Revenue - Revenue and Deferred Revenue Narratives HTML 25K
(Details)
44: R35 Revenue - Cost to obtain and fulfill a contract HTML 39K
(Details)
45: R36 Acquisitions - Summary of Purchase Consideration HTML 42K
(Details)
46: R37 Acquisitions - Shares Issued (Details) HTML 207K
47: R38 Acquisitions - Summary of Estimated Fair Values of HTML 112K
Assets Acquired and Liabilities Assumed (Details)
48: R39 Goodwill and Intangible Assets - Carrying amount HTML 25K
of goodwill (Details)
49: R40 Goodwill and Intangible Assets - Intangible assets HTML 63K
(Details)
50: R41 Fair Value Measurements (Details) HTML 39K
51: R42 Fair Value Measurements - Level 3 Contingent HTML 27K
Consideration (Details)
52: R43 Debt - Notes (Details) HTML 29K
53: R44 Debt (Details) HTML 142K
54: R45 Equity-based Compensation - Compensation expense HTML 33K
(Details)
55: R46 Equity-based Compensation - Stock Options HTML 70K
(Details)
56: R47 Equity-based Compensation - Stock Option Activity HTML 85K
(Details)
57: R48 Equity-based Compensation - Restricted Stock Units HTML 102K
(Details)
58: R49 Equity-based Compensation - Employee Stock HTML 47K
Purchase Plan (Details)
59: R50 Income Taxes (Details) HTML 34K
60: R51 Net income (Loss) Per Share Attributable to Common HTML 60K
Stockholders (Details)
61: R52 Net income (Loss) Per Share Attributable to Common HTML 50K
Stockholders - Stock Options (Details)
62: R53 Commitments and Contingencies - Legal Proceedings HTML 32K
(Details)
63: R54 Change Healthcare Joint Development Agreement HTML 56K
(Details)
66: XML IDEA XML File -- Filing Summary XML 123K
64: XML XBRL Instance -- accd-20211130x10q_htm XML 2.15M
65: EXCEL IDEA Workbook of Financial Reports XLSX 93K
6: EX-101.CAL XBRL Calculations -- accd-20211130_cal XML 170K
7: EX-101.DEF XBRL Definitions -- accd-20211130_def XML 660K
8: EX-101.LAB XBRL Labels -- accd-20211130_lab XML 1.42M
9: EX-101.PRE XBRL Presentations -- accd-20211130_pre XML 1.00M
5: EX-101.SCH XBRL Schema -- accd-20211130 XSD 180K
67: JSON XBRL Instance as JSON Data -- MetaLinks 353± 550K
68: ZIP XBRL Zipped Folder -- 0001558370-22-000200-xbrl Zip 341K
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Rajeev Singh, Chief Executive Officer of Accolade, Inc. (the “Company”), and Stephen Barnes, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
| 1. | The Company’s Quarterly Report on Form 10-Q for the period ended November 30, 2021, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and |
| 2. | The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: January 10, 2022
In Witness Whereof, the undersigned have set their hands hereto as of the 10th day of January, 2022.
/s/ Rajeev Singh /s/ Stephen Barnes
Chief Executive OfficerChief Financial Officer
“This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Accolade, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.”
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 1/11/22 | 4 | ||
| Filed on: | 1/10/22 | 8-K | ||
| For Period end: | 11/30/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/10/21 Accolade, Inc. 8-K:1,3,8,9 6/09/21 12:1.5M Toppan Merrill/FA 3/29/21 Accolade, Inc. 8-K:1,2,3,8 3/23/21 14:1.3M Toppan Merrill/FA 3/04/21 Accolade, Inc. 8-K:1,3,8,9 3/03/21 13:1.5M Toppan Merrill/FA 7/10/20 Accolade, Inc. 8-K:5,9 7/07/20 2:58K Toppan Merrill/FA 2/28/20 Accolade, Inc. S-1 39:24M Toppan Merrill-FA |